Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretrov...

Full description

Bibliographic Details
Main Authors: Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Chiara Molteni, Addolorata Masiello, Giancarlo Orofino, Barbara Menzaghi, Rita Bellagamba, Francesca Vichi, Benedetto Maurizio Celesia, Giordano Madeddu, Giovanni Francesco Pellicanò, Maria Aurora Carleo, Antonio Cascio, Andrea Parisini, Lucia Taramasso, Laura Valsecchi, Leonardo Calza, Stefano Rusconi, Eleonora Sarchi, Salvatore Martini, Olivia Bargiacchi, Katia Falasca, Giovanni Cenderello, Sergio Ferrara, Antonio Di Biagio, Paolo Bonfanti
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Viruses
Subjects:
HIV infection
ART-experienced
doravirine
rilpivirine
adverse events
metabolic safety
Online Access:https://www.mdpi.com/1999-4915/15/7/1612

Internet

https://www.mdpi.com/1999-4915/15/7/1612

Similar Items